The Delaware Court of Chancery—widely regarded as the nation’s premier forum for resolving corporate disputes—continues to play a pivotal role in shaping U.S. mergers and acquisitions. In a string of influential decisions, the court has recently allowed significant shareholder lawsuits and regulatory actions to advance, underscoring growing legal scrutiny surrounding multi-billion dollar transactions and the conduct of executives and investors involved in these deals.

Activision Blizzard–Microsoft Merger: Shareholder Claims Survive

Delaware’s Chancellor, Kathaleen McCormick, recently issued a decision keeping alive most of a shareholder lawsuit challenging the historic $75.4 billion merger between Activision Blizzard and Microsoft. The suit, brought by investors, alleges that certain aspects of the deal shortchanged Activision shareholders and failed to maximize value, while also raising questions about transparency and conflicts of interest.

The ruling, which partially granted and partially denied motions to dismiss, means that a “slimmed-down” version of investor claims will proceed. The Chancellor’s decision signals a willingness to closely review the largest technology acquisitions, especially amid a broader landscape where regulators such as the Federal Trade Commission have scrutinized the competitive impact of major tech deals. Just recently, the FTC attempted to block the deal but was ultimately unsuccessful. Microsoft’s acquisition of Activision Blizzard closed in October 2023, reshaping the video game landscape and intensifying focus on shareholder rights and oversight.

Veterans Services Company Faces Self-Dealing Allegations

The court also refused to dismiss fiduciary duty claims against executives at a leading veterans services company, following its controversial 2023 merger into a limited liability company (LLC) structure. The shareholder who brought suit alleged that the merger was structured primarily to shield company leadership from personal accountability rather than to serve the interests of public shareholders.

This case exemplifies a wider trend: Delaware courts are increasingly receptive to shareholder claims that allege transactions were designed to benefit insiders at the expense of the broader investor base. Attorneys note that the outcome could set important precedent regarding how and when leadership can use transitions from corporate to LLC status as a defensive shield, a practice that has become more frequent as companies seek flexibility and insulation from liability.

Bain Capital Faces Insider Trading Claims Over Cerevel Therapeutics Acquisition

In another high-profile development, a pension fund’s lawsuit targeting Bain Capital Investors LLC and others will move forward, after the Chancery Court found sufficient allegations of insider trading. The suit claims Bain and other private equity stakeholders improperly leveraged non-public information ahead of a secondary sale of shares in biopharma venture Cerevel Therapeutics, which was then sold to AbbVie for $8.7 billion.

The litigation draws attention to the increasingly aggressive stance courts and regulators are taking against private equity sponsors and other market insiders when allegations of information misuse or trading irregularities arise. This comes amid a record surge of global M&A activity, with the first half of 2025 already seeing over $2 trillion in announced transactions, according to financial data provider Refinitiv.

Antitrust Scrutiny and Competition Concerns in Mega-Mergers

Outside of direct shareholder litigation, firms pursuing large-scale mergers continue to face heightened antitrust scrutiny in the U.S. and Europe. Notably, HNI Corp. agreed to provide more time to antitrust regulators for review of its planned $2.2 billion acquisition of Steelcase, reflecting ongoing concerns over market consolidation in the workplace furnishings sector.

Similarly, the European Commission recently cleared Prada’s €1.25 billion ($1.47 billion) acquisition of Italian designer brand Versace, highlighting the increasingly global oversight of major deals. At the same time, the Federal Trade Commission (FTC) and UK’s Competition and Markets Authority (CMA) have launched or advanced investigations into a number of transactions in technology, medical devices, and infrastructure, reinforcing a complex and uncertain environment for dealmakers.

Additional High-Profile M&A Developments

• A beauty brand acquired by L’Oreal for $1 billion now faces litigation from its president claiming she is owed a larger share of the proceeds, reflecting the frequent post-closing disputes over earnouts and executive compensation.
• Singaporean biotech Nanyang Biologics Pte. Ltd. announced plans for a $1.5 billion public listing in the U.S. via a SPAC merger, marking a continuation of cross-border dealmaking despite increased regulatory review of foreign listings.
• Berkshire Hathaway, led by Warren Buffett, revealed its latest megadeal—a $9.7 billion all-cash acquisition of Occidental Petroleum’s chemical subsidiary OxyChem, further signaling confidence in the energy and chemical sectors.
• Axcelis Technologies and Veeco Instruments sealed a $4.4 billion all-stock merger, exemplifying the continued consolidation trend in the semiconductor production space.

In parallel, antitrust enforcement complications stemming from the U.S. government shutdown—as seen in court disputes over pausing FTC healthcare merger reviews—have created fresh questions for both regulators and companies eager to close transactions within tight timeframes.

Implications for Shareholders, Dealmakers, and Legal Advisors

These recent decisions from the Delaware Court of Chancery reinforce several key M&A realities for 2025 and beyond:

• Increased shareholder activism is leading to closer court examination of whether transaction structures unfairly benefit insiders.
• Litigation risks loom large for deals involving conflicts of interest, transparency shortcomings, or unusual corporate restructuring.
• Private equity sponsors face new scrutiny over their conduct in both public and private market transactions, particularly in cases of alleged trading on material non-public information.
• Antitrust reviews can delay or derail multi-billion dollar deals, especially in industries undergoing rapid consolidation.

The evolving landscape highlights the need for companies to boost their internal governance, ensure diligent M&A process documentation, and align executive incentives with long-term shareholder value—not just deal closure. As the complexity and stakes of global M&A activity continue to rise, Delaware’s courts remain a central arena for shaping the future of corporate governance and accountability in the era of mega-mergers.